Sealantis develops innovative products based on a proprietary platform of alga-mimetic tissue adhesives, for a variety of applications and clinical needs in surgical adhesion, leakage control, adhesion-prevention and drug delivery. The Sealantis adhesive technology mimics the underwater adherence mechanism of algae, providing it with a superior ability to stick to tissues and grafts even in a wet environment. The adhesives are bioresorbably and are protein-free, eliminating protein-related risks. Sealantis' product pipeline is focused on three products:
- Seal-V, a CE marked vascular sealant designed for the rapid control of bleeding during various vascular procedures. Seal-V has proved to be unequalled in regard to safety, efficacy and cost-effectiveness. It is strong, safe, biocompatible and biodegradable, and easy to use.
- Seal-G, a Gastro-Intestinal (GI) bioresorbable sealant designed for securing gastro-intestinal anastomoses to decrease lethal complications resulting from post-surgical leaks.
- Orthopedic Adhesion Barrier (OAB), an extra-articular bioresorbable gel, designed to speed the recovery of injured joints by preventing tissue adhesions, thereby reducing disabling complications following surgical or non-surgical joint injuries.
Sealantis was founded in 2007 by Prof. Havazelet Bianco-Peled, a world renowned expert in biopolymers, and is backed by a seasoned team of managers, scientists and top-notch medical professionals. Sealantis leverages its proprietary innovations and its team's distinct expertise to offer new approaches to surgical sealing, surgical adhesion and site-specific drug delivery.